Skip to main content
SpringerPlus

Table 1 Baseline characteristics

From: Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial

 

Placebo (N = 50)

NEPA200/0.5(N = 49)

NEPA600/1.5(N = 49)

Moxifloxacin (N = 49)

Age, years

    

 Mean (SD)

34.7 (7.12)

33.6 (6.86)

32.8 (8.36)

34.7 (7.98)

 Min–max

19–45

21–44

19–45

19–45

Gender, n (%)

    

 Male

26 (52)

27 (55)

27 (55)

26 (53)

 Female

24 (48)

22 (45)

22 (45)

23 (47)

BMI, kg/m2

    

 Mean (SD)

24.45 (2.486)

24.27 (2.608)

24.51 (2.516)

24.89 (2.674)

 Min–max

19.0–28.9

19.2–28.5

19.4–28.9

19.4–29.0

  1. BMI, body mass index; SD, standard deviation.
  2. NEPA200/0.5: 200 mg netupitant (50 mg + 150 mg) + 0.50 mg palonosetron (1 × 0.50 mg).
  3. NEPA600/1.5: 600 mg netupitant (4 × 150 mg) + 1.50 mg palonosetron (3 × 0.50 mg).
  4. Percentages are based on N.
Back to article page